Evaluation of the influence of tianeptine on the psychosomatic status of patients with ulcerative colitis in remission;Ocena wplywu tianeptyny na stan psychosomatyczny chorych na wrzodziejace zapalenie jelita grubego w okresie remisji

Polski Merkuriusz Lekarski

Volumn 31, Issue 182, 2011, Pages 92-96

  Chojnacki, C ^a   Walecka Kapica, E ^b   Klupinska G ^b   Pawlowicz, M ^a   Florkowski, A ^b   Wachowska Kelly, P ^a   Chojnacki, J ^a  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b Department of Clinical Nutrition ^*  (Poland)

Author keywords

Activity index; Emotional state; Tianeptine; Ulcerative colitis

Indexed keywords

AMINOSALICYLIC ACID; THIAZEPINE DERIVATIVE; TIANEPTINE; TRICYCLIC ANTIDEPRESSANT AGENT;

ADULT; ANXIETY; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; FEMALE; HUMAN; MALE; MIDDLE AGED; REMISSION; ULCERATIVE COLITIS;

ADULT; AMINOSALICYLIC ACID; ANTIDEPRESSIVE AGENTS, TRICYCLIC; ANXIETY; COLITIS, ULCERATIVE; DEPRESSION; FEMALE; HUMANS; MALE; MIDDLE AGED; REMISSION INDUCTION; THIAZEPINES; YOUNG ADULT;

EID: 80052753083     PISSN: 14269686     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (40)

1. Adrizzone S., Bianchi Porro G.: Comparative tolerability of therapies for ulcerative colitis. Drug Safety 2002; 25: 561-582.
2. Adrizzone S., Bianchi Porro G.: Inflammatory bowel disease: new insight into pathogenesis and treatment. J. Intern. Med. 2002; 252: 475-496. (Pubitemid 35454325)
3. Barratt S.M., Leeds J.S., Robinson K. i wsp.: Reflux and irritable bowel syndrome are negative predictors of quality of life in coeliac disease and Inflammatory bowel disease. Eur. J. Gastroenterol. Hepatol. 2011; 23, (2): 159-165.
4. Beneke M.: Methodological investigations of the Hamilton Anxiety Scale. Pharmacopsychiatry 1987; 20, (6): 249-255. (Pubitemid 18001605)
5. Bixquert-Jiménez M., Bixquert-Pla L.: Antidepressant therapy in functional gastrointestinal disorders. Gastroenterol. Hepatol. 2005; 28, (8): 485-492. (Pubitemid 41530543)
6. Blumberg R.S.: Inflammation in the intestinal tract: pathogenesis and treatment. 2009; 27, (4): 455-464.
7. Bolling-Stemevald E., Lauritsen K., Aalykke C. i wsp.: Effect of profound acid suppression in functional dyspepsia: a double-blind, randomized, placebo-controlled trial. Scand. J. Gastroenterol. 2002; 37: 1395-1402. (Pubitemid 36054199)
8. Bolton V.N., Bassil A.K., Lee K. i wsp.: Inhibition by tianeptine of neuro-nally mediated contractions in the rat isolated gastrointestinal tract. Pharmacol. Res. 2008; 57, (5): 339-343.
9. Bryant R.V., van Langenberg D.R., Holtmann G.J. i wsp.: Functional gastrointestinal disorders in inflammatory bowel disease: Impact on quality of life and psychological status. J Gastroenterol Hepatol 2011 (w druku).
10. Castle M.Z., Silk D.B., Libby G.W.: Review article: The rationale for antidepressant therapy in functional gastrointestinal disorders. Aliment. Pharmacol. Ther. 2001; 19, (9): 969-979. (Pubitemid 38657377)
11. Chang L., Drossman DA: Leki psychotropowe I postepowanie z chorym z czynnosciowymi zaburzeniami ze strony przewodu pokarmowego. W: Gastrologia i choroby wafroby (red. B. Skrzydfo-Radomańska). Czelej, Lublin 2007; 277-283.
12. Curzon G.: Nowy lek przeciwdepresyjny: tianeptyna - oryginalne wlaści-wości farmakologiczne I znaczenie kliniczne. Lek I Depresja 1996; suppl. 1: 30-34.
13. Dalbende C, Contesse V., Mocaer E. i wsp.: The novel antidepressant tianeptine, reduces stress-evoked stimulation of the hypothalamo - pituitary-adrenal axis. Eur. J. Pharmacol. 1991; 202: 391-396.
14. Diamond M., Kelly J.P., Connor T.J.: Antidepressants suppress production of the Thl cytokine interferon-gamma, independent of monoamine transporter blockade. Eur. Neuropsychopharmacol. 2006; 16, (7): 481-490. (Pubitemid 44311000)
15. Dürk T., Panther E., Müller T. i wsp.: 5-Hydroxytryptamine modulates cytokine and chemokine production in LPS-primed human monocytes via stimulation of different 5-HTR subtypes. Int. Immunol. 2005; 17, (5): 599-606. (Pubitemid 41417857)
16. Farrokhyar F., Marshall J.K., Easterbrook B. i wsp.: Functional gastrointestinal disorders and mood disorders in patients with inactive inflammatory bowel disease: prevalence and impact on health. Inflamm. Bowel. Dis. 2006; 12, (1): 38-46. (Pubitemid 43032450)
17. Ford A.C., Talley N.J., Schoenfeld P.S. i wsp.: Efficacy of antidepressants and psychological therapies in irritable bowel syndrome: systematic review and meta-analysis. Gut 2009; 58, (3): 367-378.
18. Head KA, Jurenka J.S.: Inflammatory bowel disease part I: Ulcerative colitis - pathophysiology and conventional and alternative treatment. Alternative Medicine Review 2003; 8, (3): 247-283. (Pubitemid 37099887)
19. Jackson J.L., O'Malley P.G., Tomkins G. i wsp.: Treatment of functional gastrointestinal disorders with antidepressant medications: a meta-analysis. Am. J. Med. 2000; 108, (1): 65-72. (Pubitemid 30058279)
20. Kasper S., Olie J.P.: A meta-analysis of randomized controlled trials of tianeptine versus SSRI in the short-term treatment of depression. Eur. Psychiatry. 2002; 17 suppl. 3: 331-340. (Pubitemid 34839396)
21. Kato G., Weitsch A.F.: Neurochemical profile of tianeptine, a new antidepressant drug. Clin. Neuropharmacol., 1988; 11 suppl. 2: 43-50.
22. Lechin F., van der Dijs B., Hernandez G. i wsp.: Acute effects of tianeptine on circulating neurotransmitters and cardiovascular parameters. Prog. Neuropsychopharmacol. Biol. Psychiatry. 2006; 30, (2): 214-222. (Pubitemid 43288061)
23. Lechin F., van der Dijs B., Lechin A.E.: Treatment of bronchial asthma with tianeptine. Methods. Find. Exp. Clin. Pharmacol. 2004; 26, (9): 697-701. (Pubitemid 40075858)
24. León-Ponte M., Ahem G.P., O'Connell P.J.: Serotonin provides an accessory signal to enhance T-cell activation by signaling through the 5-HT7 receptor. Blood, 2007; 109, (8): 3139-3146. (Pubitemid 46572497)
25. Loke Y.K., Trivedi A.N., Singh S.: Meta-analysis: gastrointestinal bleeding due to interaction between selective serotonin uptake inhibitors and nonsteroidal anti-inflammatory drugs. Aliment. Pharmacol. Ther. 2008; 2, (1): 31-40. (Pubitemid 350212624)
26. Mikocka-Walus AA, Turnbull D.A., Andrews J.M. i wsp.: The effect of functional gastrointestinal disorders on psychological comorbidity and quality of life in patients with inflammatory bowel disease. Aliment Pharmacol. Ther. 2008; 28, (4): 475-483. (Pubitemid 352033281)
27. Mikocka-Walus A.A., Turnbull D.A., Moulding N.T. i wsp.: It doesnl do any harm, but patients feel better: a qualitative exploratory study on ga-stroenterologists' perspectives on the role of antidepressants in inflammatory bowel disease. BMC Gastroenterol. 2007; 7: 38-42.
28. Mort J.R., Aparasu R.R., Baer R.K.: Interaction between selective serotonin reuptake inhibitors and nonsteroidal antiinflammatory drugs: review of the literature. Pharmacotherapy. 2006; 26, (9): 1307-1313. (Pubitemid 44306891)
29. O'Connell P. J., Wang X., Leon-Ponte M. i wsp.: A novel form of immune signaling revealed by transmission of the inflammatory mediator serotonin between dendritic cells and T cells. Blood. 2006; 107, (3): 1010-1017. (Pubitemid 43156299)
30. Pache I., Rogler G., Felley C: TNF-alpha blockers in inflammatory bowel diseases: practical consensus recommendations and a user's guide. Swiss. Med. Wkly. 2009; 139, (19-20): 278-287.
31. Roumestan C, Michel A., Bichon F. i wsp.: Anti-inflammatory properties of desipramine and fluoxetine. Respir. Res. 2007; 8: 35-36.
32. Rybakowski J.: Famtakologiczne leczenie depresji. Przew. Lek. 2001; 4, ( 6); 48-56.
33. Rybakowski J.: Polskie badania nad tianeptyna,. Lek I Depresja 1996; suppl. 1: 63-69.
34. Sandbom W.J., Stenson W.F., Brynskov J. i wsp.: Safety ofcelecoxib in patients with ulcerative colitis in remission: a randomized, placebo-controlled, pilot study. Clin. Gastroenterol. Hepatol. 2006; 4, ( 2): 203-211. (Pubitemid 43199691)
35. Simrén M., Axelsson J., Gillberg R. i wsp.: Quality of life in inflammatory bowel disease In remission: the impact of IBS-like symptoms and associated psychological factors. Am. J. Gastroenterol. 2002; 97, (2): 389-396. (Pubitemid 34160766)
36. Suleyman H., Cadirci E., Albayrak A. i wsp.: Comparative study on the gastroprotective potential of some antidepressants in indomethacin-in-duced ulcer in rats. Chem. Biol. Interact. 2009; 180, (2): 318-324.
37. Tomaselli G, Modestin J.: Repetition of serotonin syndrome after re-exposure to SSRI-a case report. Pharmacopsychiatry. 2004; 37, (5): 236-238. (Pubitemid 39286927)
38. Vukovic O., Marie N.P., Britvic D. i wsp.: Efficacy, tolerability and safety of tianeptine in special populations of depressive patients. Psychiatr. Da-nub. 2009; 21, (2): 194-198.
39. Wessinger S., Kaplan M., Choi L. i wsp.: Increased use of selective serotonin reuptake inhibitors in patients admitted with gastrointestinal haemorrhage: a multicentre retrospective analysis. Aliment. Pharmacol. Ther. 2006; 23, (7): 937-944.
40. Wilde M.I., Benfield P.: Tianeptine. A review of its pharmacodynamic and pharmacokinetic properties and therapeutic efficacy in depression and coexisting anxiety and depression. Drugs 1995; 49, ( 3): 411-439.